#Sweden #Gothenburg #Getinge #ECLS #Cardiosave

Getinge's Strong Q4 and Full-Year Results for 2025

Getinge has announced a remarkable performance in its fourth quarter and full-year results for 2025, showcasing strong organic growth and solid cash flow despite facing significant challenges including tariffs and currency fluctuations. As reported by Mattias Perjos, CEO, the company achieved an organic growth of 4.9% for the entire year, aligning with the upper end of its forecast and reflecting resilience in its operational strategy.

During the fourth quarter, Getinge noted a surge in demand for consumables related to Extracorporeal Life Support (ECLS) therapy and acute care therapies, which were pivotal in driving the company’s success. The sales performance was particularly notable in segments such as Transplant Care and ventilators. This success allowed Getinge’s Surgical Workflows division to maintain its leading position in the market, particularly in operating tables, as it entered 2026 with a robust order backlog.

Financial Highlights

In terms of financial performance, Getinge’s net sales rose organically by 1.2% in Q4, leading to increased order intake by 2.3%. For the full year, net sales also demonstrated healthy growth at 4.9%, while the order intake increased by 3.5%. The company reported adjusted gross profit of SEK 17,607 million for the year, translating to a margin of 50.4%, slightly up from the previous year.

Despite external pressures from tariffs and currency effects, which accounted for over SEK 1 billion compared to the previous year, Getinge managed to maintain an adjusted EBITA margin of 14.0% for the year, reflecting superior underlying profitability driven by ongoing price adjustments and cost management initiatives. The reported adjusted earnings per share for 2025 stood at SEK 11.29, showcasing slight declines from the previous year’s figures but underscoring the company's commitment to shareholder value, evidenced by a proposed dividend of SEK 4.75 per share.

Innovative Developments

In addition to its financial performance, Getinge is making strides in product development with significant launches, including Automatiq—a next-generation automation system focused on sterile reprocessing. This product leverages smart robotics technology aimed at enhancing patient safety and efficiency in clinical processes, with initial orders already secured.

The company has also made headway in regulatory compliance, crucial for maintaining market competitiveness. Its Rotaflow consumables in ECLS received EU MDR approval, and the iCast covered stent secured PMA for two additional versions, strengthening its market position in the U.S. Furthermore, deliveries of the intra-aortic balloon pump Cardiosave are anticipated to begin in mid-2026 following the reinstatement of its CE certificate, reflecting strong market demand.

Outlook for 2026

Looking ahead, Getinge faces heightened geopolitical uncertainty, which may impact market dynamics. However, based on the projected underlying demand, the company forecasts organic sales growth of 3–5% for 2026. Perjos expressed gratitude towards employees and customers for their support and efforts to create enduring value within the healthcare sector.

In conclusion, 2025 was a year of significant progress for Getinge, underpinned by effective management strategies and innovative product developments. As the company continues to navigate through the complexities of the healthcare landscape, its focus remains steadfast on enhancing clinical outcomes and optimizing operational workflows across its diverse product offerings.

• ---

Key Financials Summary

• - Q4 Organic Sales Growth: 1.2%
• - Full-Year Organic Sales Growth: 4.9%
• - Adjusted Gross Profit: SEK 17,607 million (50.4% margin)
• - Adjusted EBITA: SEK 4,880 million (14.0% margin)
• - Earnings per Share: SEK 11.29
• - Proposed Dividend: SEK 4.75

This report illustrates the strategic advancements and robust health of Getinge even amid industry challenges, paving the way for sustained growth and innovation in 2026.